Cirqle Biomedical is seeking a talented intern to take part in the development of a groundbreaking non-hormonal contraceptive for women. At Cirqle Biomedical, our mission is to reinvent contraception. By leveraging the body’s own mucus barrier we are developing the first non-hormonal, on-demand contraceptive for women that could impact millions of lives. We are a team with ambitious goals, set to do good and to tackle big challenges at a fast pace and with the highest quality.

As a Business Development Intern you will work closely with the CEO on key business development activities. Our goal is to provide you hands on experience from an early stage life science startup.

Your key responsibilities are:

• Developing our investor pitch deck

• Investor lead development

• Build dataroom

• Financial reporting

• Take on flexible responsibilities if and when necessary 

Ideal profile

• You are a M.Sc. business student with an excellent academic track record who is familiar with startups

• Able to join the company for at least 3 month

• Interested in the intersection between consumer products, biotechnology, and medical devices

• Ability to work independently and take full ownership of your tasks

• A natural communicator with good English communication skills

• Comfortable contacting people 

• Experience from the life science industry is a plus but not a requirement 

• Authorised to work in Denmark

Your office is located in beautiful Copenhagen. We work in an international and entrepreneurial environment and you will have access to fantastic work facilities.

By joining Cirqle you will become part of an international and dynamic team that is motivated by transforming new science into commercial products that makes a real difference to users. We are a pre-clinical startup based in Copenhagen and Stockholm aiming to revolutionize contraception for women with a non-hormonal, worry-free solution. The underlying technology has been developed at The Royal Institute of Technology in Stockholm. Following successful pre-clinical data, the technology is being developed into a product for the first in-human clinical trial with the support of leading life science investors.